The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Plasma Exchange and Glucocorticoids in Severe ANCA-Associated Vasculitis
Open accessAbstract
BACKGROUND: More effective and safer treatments are needed for antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis. METHODS: of body-surface area or diffuse pulmonary hemorrhage). Patients were randomly assigned to undergo plasma exchange (seven plasma exchanges within 14 days after randomization) or no plasma exchange (control group). Patients were also randomly assigned to follow either a standard-dose regimen or a reduced-dose regimen of oral glucocorticoids. Patients were followed for up to 7 years for the primary composite outcome of death from any cause or end-stage kidney disease (ESKD). RESULTS: Death from any cause or ESKD occurred in 100 of 352 patients (28.4%) in the plasma-exchange group and in 109 of 352 patients (31.0%) in the control group (hazard ratio, 0.86; 95% confidence interval [CI], 0.65 to 1.13; P = 0.27). The results were similar in subgroup analyses and in analyses of secondary outcomes. We also assessed the noninferiority of a reduced-dose regimen of glucocorticoids to a standard-dose regimen, using a noninferiority margin of 11 percentage points. Death from any cause or ESKD occurred in 92 of 330 patients (27.9%) in the reduced-dose group and in 83 of 325 patients (25.5%) in the standard-dose group (absolute risk difference, 2.3 percentage points; 90% CI, -3.4 to 8.0), which met the criterion for noninferiority. Serious infections at 1 year were less common in the reduced-dose group than in the standard-dose group (incidence rate ratio, 0.69; 95% CI, 0.52 to 0.93), but other secondary outcomes were similar in the two groups. CONCLUSIONS: Among patients with severe ANCA-associated vasculitis, the use of plasma exchange did not reduce the incidence of death or ESKD. A reduced-dose regimen of glucocorticoids was noninferior to a standard-dose regimen with respect to death or ESKD. (Funded by the U.K. National Institute for Health Research and others; PEXIVAS Current Controlled Trials number, ISRCTN07757494; ClinicalTrials.gov number, NCT00987389.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
EuroQol: the current state of play
Brooks, R. (1996) · Health Policy · doi:10.1016/0168-8510(96)00822-6 · Cited by 5,815
Rituximab versus Cyclophosphamide for ANCA-Associated Vasculitis
Stone, J. H., Merkel, P. A., Spiera, R., Seo, P., Langford, C. A., Hoffman, G. S., Kallenberg, C. G. M., St. Clair, E. W., Turkiewicz, A., Tchao, N. K., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0909905 · Cited by 2,762
Self-citationPadmanabhan, A., Connelly‐Smith, L., Aqui, N., Balogun, R. A., Klingel, R., Meyer, E., Pham, H. P., Schneiderman, J., Witt, V., Wu, Y., et al. (2019) · Journal of Clinical Apheresis · doi:10.1002/jca.21705 · Cited by 2,230
Rituximab versus Cyclophosphamide in ANCA-Associated Renal Vasculitis
Jones, R. B., Cohen Tervaert, J. W., Hauser, T., Luqmani, R., Morgan, M. D., Peh, C. A., Savage, C. O., Segelmark, M., Tesar, V., van Paassen, P., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0909169 · Cited by 1,748
Self-citationInternational Conference on Harmonisation
Guy, R. C. (2014) · Encyclopedia of Toxicology · doi:10.1016/b978-0-12-386454-3.00861-7 · Cited by 1,478
Jayne, D., Rasmussen, N., Andrassy, K., Bacon, P., Tervaert, J. W. C., Dadoniené, J., Ekstrand, A., Gaskin, G., Gregorini, G., de Groot, K., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa020286 · Cited by 1,348
Self-citationJayne, D. R. W., Gaskin, G., Rasmussen, N., Abramowicz, D., Ferrario, F., Guillevin, L., Mirapeix, E., Savage, C. O. S., Sinico, R. A., Stegeman, C. A., et al. (2007) · Journal of the American Society of Nephrology · doi:10.1681/asn.2007010090 · Cited by 1,125
Self-citationXiao, H., Heeringa, P., Hu, P., Liu, Z., Zhao, M., Aratani, Y., Maeda, N., Falk, R. J., & Jennette, J. C. (2002) · Journal of Clinical Investigation · doi:10.1172/jci15918 · Cited by 1,005
Long-term patient survival in ANCA-associated vasculitis
Flossmann, O., Berden, A., de Groot, K., Hagen, C., Harper, L., Heijl, C., Höglund, P., Jayne, D., Luqmani, R., Mahr, A., et al. (2011) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2010.137778 · Cited by 939
Self-citationXiao, H., Heeringa, P., Hu, P., Liu, Z., Zhao, M., Aratani, Y., Maeda, N., Falk, R. J., & Jennette, J. C. (2002) · Journal of Clinical Investigation · doi:10.1172/jci0215918 · Cited by 919
Cited by
Glucocorticoids and natural killer cells: A suppressive relationship
Muscari, I., Fierabracci, A., Adorisio, S., Moretti, M., Cannarile, L., Thi Minh Hong, V., Ayroldi, E., & Delfino, D. V. (2022) · Biochemical Pharmacology · doi:10.1016/j.bcp.2022.114930 · Cited by 32
Metadata
- Authors
- Walsh, M., Merkel, P. A., Peh, C.-A., Szpirt, W. M., Puéchal, X., Fujimoto, S., Hawley, C. M., Khalidi, N., Floßmann, O., Wald, R., Girard, L. P., Levin, A., Gregorini, G., Harper, L., Clark, W. F., Pagnoux, C., Specks, U., Smyth, L., Tesar, V., Ito-Ihara, T., de Zoysa, J. R., Szczeklik, W., Flores-Suárez, L. F., Carette, S., Guillevin, L., Pusey, C. D., Casian, A. L., Brezina, B., Mazzetti, A., McAlear, C. A., Broadhurst, E., Reidlinger, D., Mehta, S., Ives, N., & Jayne, D. R. W.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2020-02-13
- Volume
- 382
- Issue
- 7
- Pages
- 622-631
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W3004897282
- Cited by
- 893
- References
- 34
- FWCI
- 62.92
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Plasma Exchange and Glucocorticoids in Severe ANCA-Associated Vasculitis. https://app.cochat.ai/papers/10.1056/nejmoa1803537
- The paper
- Walsh, M., Merkel, P. A., Peh, C.-A., Szpirt, W. M., Puéchal, X., Fujimoto, S., Hawley, C. M., Khalidi, N., Floßmann, O., Wald, R., Girard, L. P., Levin, A., Gregorini, G., Harper, L., Clark, W. F., Pagnoux, C., Specks, U., Smyth, L., Tesar, V., . . . Jayne, D. R. W. (2020). Plasma Exchange and Glucocorticoids in Severe ANCA-Associated Vasculitis. New England Journal of Medicine. https://doi.org/10.1056/nejmoa1803537
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
